BPC-157
Also known as: Body Protection Compound 157, PL 14736
BPC-157 is a synthetic peptide fragment derived from a protein found in gastric juice. It is widely discussed online for reported tissue-healing and anti-inflammatory effects, but human clinical evidence remains very limited.
- Category
- Healing & Recovery
- Reported half-life
- Not well established; some animal data suggest a short plasma half-life of minutes, though local tissue effects are reported to persist longer
- Common forms
- Lyophilised powder for reconstitution, Injectable solution, Oral capsules (gut-focused research)
- Research status
- Not approved for human use in Australia; investigated in animal and preclinical research settings only. No marketed therapeutic product.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to support healing of tendon, ligament and muscle injuries (mostly animal studies)
- Claimed to protect the gastrointestinal lining and aid gut-related complaints
- Users report reduced joint and soft-tissue discomfort
- Early research suggests it may influence angiogenesis (new blood-vessel formation)
How it is reported to work
BPC-157 is reported to promote tissue repair by upregulating growth-factor pathways and supporting the formation of new blood vessels (angiogenesis). Studies in animals suggest it may interact with the nitric oxide system and influence collagen organisation during healing. These mechanisms are drawn largely from rodent models, and how they translate to humans is not established.
Background
BPC-157 (Body Protection Compound 157) is a synthetic peptide consisting of a 15-amino-acid sequence said to be derived from a protective protein found in human gastric juice. It has become one of the most talked-about “recovery” peptides online, particularly among people interested in sports injuries and gut health. It is important to understand from the outset that this page is educational information, not medical advice, and that the effects described below are reported and claimed rather than medically established.
What the research actually shows
Most of the published BPC-157 research comes from animal models, primarily rats. These studies suggest possible effects on tendon, ligament, muscle and gut-tissue healing. However, well-designed, peer-reviewed human clinical trials are largely absent. This is a critical gap: promising rodent data does not automatically translate into proven human benefits or safety.
| Evidence type | What exists | What it means |
|---|---|---|
| Animal studies | Numerous rodent papers | Hypothesis-generating only |
| Human trials | Very limited / early-stage | Cannot confirm efficacy |
| Regulatory approval | None in Australia | Not a recognised medicine |
What people use it for (reported)
Online communities report using BPC-157 in attempts to speed recovery from soft-tissue injuries, calm gut irritation, and reduce joint discomfort. These are anecdotal reports, not validated outcomes. Studies suggest mechanisms involving angiogenesis and growth-factor signalling, but reported benefits should not be treated as established facts.
Things to be aware of
BPC-157 is not approved for human use in Australia. The quality, purity and contents of grey-market products cannot be verified by consumers, which is one reason independent testing is discussed within this community. Because rigorous human safety data does not exist, potential long-term risks are simply unknown.
If you have an injury or health concern, the appropriate step is to consult a qualified healthcare professional rather than self-experimenting. Nothing here should be read as a recommendation to obtain or use BPC-157. Claimed effects remain unproven, and this article exists to help readers understand the compound and the surrounding evidence, not to promote it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to speed recovery from tendon, ligament and muscle injuries
- Users report reduced joint and soft-tissue discomfort
- Reported to soothe gut irritation and protect the stomach lining
- Anecdotally reported to reduce localised inflammation around injuries
- Reported to be well tolerated by many users at commonly reported doses
Common side effects
- Injection-site irritation, redness or bruising
- Mild nausea or stomach upset, particularly with oral use
- Fatigue or light-headedness reported by some users
- Headaches in some reports
Rare / serious side effects
- Heart palpitations or changes in blood pressure reported anecdotally
- Unexpected reactions linked to impurities in unregulated grey-market vials
- Allergic-type reactions at the injection site
- Unknown long-term effects given the absence of human safety trials
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of BPC-157. Listed so you can make an informed decision, not to suggest any use is safe.
- Because BPC-157 is reported to promote angiogenesis (new blood-vessel growth), there is concern that overuse could theoretically feed abnormal tissue growth, an unproven but frequently raised risk
- Prolonged continuous use far beyond reported short cycles is discouraged in communities due to entirely unknown long-term safety
- Using unverified grey-market product is reported to risk contamination, wrong dosing and bacterial infection from poor reconstitution or non-sterile technique
- Stacking multiple healing peptides at once is reported to make it impossible to attribute side effects or judge what is actually working
- Self-treating a serious injury with BPC-157 instead of seeking care is reported to risk masking or worsening the underlying problem
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Some users report reduced discomfort within the first week, with healing-related changes reported to build over several weeks.
First effects
Reduced discomfort within days
Noticeable change
Improved injury function ~3-4 weeks
Clear results
Reported healing progress by ~8 weeks
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take BPC-157. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection (reported near the injury site or systemically; oral capsules reported for gut-focused goals) |
|---|---|
| Typical reported dose | Reported community figures of roughly 200–500 mcg per dose |
| Frequency | Reported as 1–2× daily |
| Cycle length | Reported short cycles of about 4–6 weeks (sometimes extended to ~8 weeks for stubborn injuries), then a break |
Reported reconstitution (mg → units)
Worked example only: a 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL. A 250 mcg (0.25 mg) dose ≈ 0.1 mL = 10 units on a U-100 insulin syringe. A 500 mcg (0.5 mg) dose ≈ 0.2 mL = 20 units.
Work out the units for your vial → CalculatorCommonly reported community patterns describe short cycles of roughly 4 to 6 weeks, sometimes extended to 8 weeks for stubborn injuries, often with daily injections near the injury site before taking time off. Oral forms are reported for gut-focused goals. These are reported patterns only, not a recommendation, and no dose is medically validated for humans.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Commonly reported together as a recovery pair, with users reporting complementary tissue-repair effects
Reported as a more stable BPC-157 relative and sometimes compared or rotated
Reported to be added for recovery and sleep support alongside healing peptides
Safety notes
BPC-157 has not been approved by the TGA for human use in Australia, and its long-term safety in people has not been established in controlled trials. Reported side effects are poorly documented because rigorous human data is scarce. Anyone considering it should speak with a qualified healthcare professional first.